Last quarter (Q4 2022), Proteome Sciences's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Proteome Sciences's net income was £―. See Proteome Sciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	£ 7.78M	£ 5.13M	£ 4.75M	£ 4.66M	£ 3.05M
Cost of Revenue	-	£ 3.01M	£ 2.17M	£ 2.17M	£ 1.70M	£ 1.18M
Gross Profit	-	£ 4.77M	£ 2.96M	£ 2.58M	£ 2.95M	£ 1.87M
Operating Expense	-	£ 3.28M	£ 2.59M	£ 2.04M	£ 2.65M	£ 3.24M
Operating Income	-	£ 1.49M	-	£ 549.00K	£ 299.00K	£ -1.37M
Net Non Operating Interest Income Expense	-	£ -473.00K	£ -294.00K	£ -304.00K	£ -335.00K	£ -289.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ 1.25M	£ 72.00K	£ 245.00K	£ -36.00K	£ -1.66M
Tax Provision	-	£ -70.00K	-	£ -50.00K	£ -185.00K	£ -346.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ 1.32M	-	£ 295.00K	£ 149.00K	£ -1.31M
Basic EPS	-	-	-	£ <0.01	£ <0.01	£ >-0.01
Diluted EPS	-	-	-	£ <0.01	£ <0.01	£ >-0.01
Basic Average Shares	-	£ 295.18M	£ 295.18M	£ 295.18M	£ 295.18M	£ 295.18M
Diluted Average Shares	-	£ 309.02M	£ 301.85M	£ 295.18M	£ 295.18M	£ 295.18M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	£ 63.00K	£ 60.00K	£ 322.00K
Total Expenses	-	£ 6.29M	-	£ 4.20M	£ 4.36M	£ 4.42M
Net Income From Continuing And Discontinued Operation	-	£ 1.32M	£ 72.00K	£ 295.00K	£ 149.00K	£ -1.31M
Normalized Income	-	£ 1.19M	£ 58.32K	£ 295.00K	£ 149.00K	£ -1.31M
Interest Expense	-	-	-	£ 304.00K	£ 335.00K	£ 289.00K
EBIT	-	£ 1.73M	£ 366.00K	£ 549.00K	£ 299.00K	£ -1.37M
EBITDA	-	£ 2.13M	£ 579.00K	£ 714.00K	£ 388.00K	£ -1.14M

Currency in GBP

Proteome Sciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing